Literature DB >> 9500469

Reduced angiogenesis and tumor progression in gelatinase A-deficient mice.

T Itoh1, M Tanioka, H Yoshida, T Yoshioka, H Nishimoto, S Itohara.   

Abstract

Matrix proteolysis is thought to play a crucial role in several stages of tumor progression, including angiogenesis, and the invasion and metastasis of tumor cells. We investigated the specific role of gelatinase A (matrix metalloproteinase 2) on these events using gelatinase A-deficient mice. In these mice, tumor-induced angiogenesis was suppressed according to dorsal air sac assay. When B16-BL6 melanoma cells or Lewis lung carcinoma cells were implanted intradermally, the tumor volumes at 3 weeks after implantation in the gelatinase A-deficient mice decreased by 39% for B16-BL6 melanoma and by 24% for Lewis lung carcinoma (P < 0.03 for each tumor). The number of lung colonies of i.v. injections fell by 54% for B16-BL6 melanoma and 77% for Lewis lung carcinoma (P < 0.014 and P < 0.0015, respectively). These results indicated that host-derived gelatinase A plays an important role in angiogenesis and tumor progression, suggesting the usefulness of gelatinase A inhibitors for anticancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9500469

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  218 in total

Review 1.  A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma.

Authors:  L Yan; M A Moses
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 2.  Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention.

Authors:  W G Stetler-Stevenson
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

Review 3.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

Review 4.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

5.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis.

Authors:  G Bergers; R Brekken; G McMahon; T H Vu; T Itoh; K Tamaki; K Tanzawa; P Thorpe; S Itohara; Z Werb; D Hanahan
Journal:  Nat Cell Biol       Date:  2000-10       Impact factor: 28.824

6.  TGF-beta3-induced palatogenesis requires matrix metalloproteinases.

Authors:  L Blavier; A Lazaryev; J Groffen; N Heisterkamp; Y A DeClerck; V Kaartinen
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

7.  Matricellular proteins as modulators of cell-matrix interactions: adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2.

Authors:  Z Yang; T R Kyriakides; P Bornstein
Journal:  Mol Biol Cell       Date:  2000-10       Impact factor: 4.138

Review 8.  The impact of anti-angiogenic agents on cancer therapy.

Authors:  Dieter Marmé
Journal:  J Cancer Res Clin Oncol       Date:  2003-09-16       Impact factor: 4.553

9.  Systems-level analysis of proteolytic events in increased vascular permeability and complement activation in skin inflammation.

Authors:  Ulrich auf dem Keller; Anna Prudova; Ulrich Eckhard; Barbara Fingleton; Christopher M Overall
Journal:  Sci Signal       Date:  2013-01-15       Impact factor: 8.192

10.  Matrix metalloproteinase-9 facilitates glial scar formation in the injured spinal cord.

Authors:  Jung-Yu C Hsu; Lilly Y W Bourguignon; Christen M Adams; Karine Peyrollier; Haoqian Zhang; Thomas Fandel; Christine L Cun; Zena Werb; Linda J Noble-Haeusslein
Journal:  J Neurosci       Date:  2008-12-10       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.